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GENERAL COMMENTS
The reported work is original and probably unique. It may be of interest for ADC redears, but it should be improved as it can be also useful. Concerning the considered period: 22 May 2009 is too distant an update is necessary.
A rate of PK-PD studies between adults and children should be interesting, also a discussion of different studied drugs vs age. A few details about drugs and clinical conditions taken into account in retrived trials should be reported and discussed. A comparison with the EMA list of priorities should be useful.
The PK-PD laking data is only a small part of the off-label scenario, even if authors underline often this association.
From the clinical point of view it should be interesting to know what these trials have produced or will produce for a better use of medicines in children in considered therapeutic conditions.
REVIEWER

Dr Helen Sammons
Associate Professor of Child Health University of Nottingham
GENERAL COMMENTS
Thank you for asking me to review this interesting paper. There are still few clinical trials of pharmacokinetics (PK) performed in children and this paper helps highlight this. It provides a clear review of the current situation of PK within research currently taking place.The methodology was clear and the data extraction robust. It gives new original data on the current research situation.
The conclusions on the topic and what the paper adds was sound and adds to the literature.My further comments for publication are below:
Major points: 1) A brief summary of the registers making up the ICTRP would be helpful and summary of the regions in the world they cover. This would allow the reader to put data presented later into perspective on where the clinical trials took place.
2) There were 1075 trials investigating a medicine, of which 245 collected PK data. The paper then breaks these down into regions of the world. It would have been helpful to not only see the percentage of total PK studies taking place in each region (table 1) but to be able to quantify this by the number of trials taking place in each region. So, for example, there were 15 PK trials in north africa which were 6% of the total PK trials. Were these all the trials in north africa or only a small percentage? This then needs to be quantified in the discussion. Is there just more research in N America, but is PK still neglected in the same proportion of studies? This needs quantifying in the article and abstract.
3) Did they review any of the trials not collecting PK data to see if it would have been relevant to do so? 4)Pharmacodynamic data in only 1/5 of PK studies was mentionedthis needs to be discussed along with the phase of the study as 27% were phase one and others did not specify. 2) The data only contained trials registered on the ICTRP, not the whole world. How inclusive is it?
ADC VERSION -AUTHOR RESPONSE
We have replied to the peer-reviewers' comments below in italic.
Reviewer 1 (Maurizio Bonati) Comments for the Author...
The reported work is original and probably unique. It may be of interest for ADC readers, but it should be improved as it can be also useful. Concerning the considered period: 22 May 2009 is too distant an update is necessary.
We agree that it would be very interesting to update this study with a dataset from a more recent date. We even address this point in our discussion (" … it is of great importance that the collection of pharmacokinetic data in clinical trials in children continues to be monitored in the future.") It is however not feasible for us to conduct this update for the purpose of this publication.
A rate of PK-PD studies between adults and children should be interesting, also a discussion of different studied drugs vs age.
Indeed a rate of PK-PD studies between adults and children would be interesting. However, since our dataset was created by use of a search filter specifically designed for trials in children (the "Clinical Trials in Children (CTC) search filter"), there are no studies of adults in our sample, and it is also not possible to add these.
We agree that more information on differences between the types of trials that are conducted in different age groups would make a useful addition to our article. We have therefore added Figure 3 , showing the differences in studied health conditions or problems between different age groups. The PK-PD lacking data is only a small part of the off-label scenario, even if authors underline often this association.
We agree, since our study focused on pharmacokinetic (and dynamic) data collection, we have put emphasis on these data in our introduction and discussion.
Although this is an interesting suggestion, we feel that linking the records in our sample to concomitant publications is beyond the scope of our study. Our research focused on highlighting the possibilities that clinical trials registration brings to comprehensively assess the state of ongoing research in a particular research area, in order to inform priority setting for this research.
Maurizio Bonati
Reviewer 2 (Helen Sammons) Comments for the Author... Thank you for asking me to review this interesting paper. There are still few clinical trials of pharmacokinetics (PK) performed in children and this paper helps highlight this. It provides a clear review of the current situation of PK within research currently taking place.The methodology was clear and the data extraction robust. It gives new original data on the current research situation.
The conclusions on the topic and what the paper adds was sound and adds to the literature. My further comments for publication are below:
We have added this in the Methods section.
2) There were 1075 trials investigating a medicine, of which 245 collected PK data. The paper then breaks these down into regions of the world. It would have been helpful to not only see the percentage of total PK studies taking place in each region (table 1) but to be able to quantify this by the number of trials taking place in each region. So, for example, there were 15 PK trials in north africa which were 6% of the total PK trials. Were these all the trials in north africa or only a small percentage? This then needs to be quantified in the discussion. Is there just more research in N America, but is PK still neglected in the same proportion of studies?This needs quantifying in the article and abstract.
We thank the reviewer for this very good suggestion. We have performed additional data collection on all the trials that did not report to collect PK data in our study sample, and added the information that is requested (Table 1) We would like to extend our gratitude to both reviewers for their careful consideration of our paper. Their suggestions have allowed us to make substantial improvements to our manuscript that shed more light on this important topic.
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THE STUDY STROBE statement adhered to GENERAL COMMENTS
This article is very important for progress in medicinines testing in the paediatric field. This revised version submitted here is much improved and now addresses the research question well and clearly.
